Neoprospecta Overview

  • Year Founded
  • 2011

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 50

Employees

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $8.28M

Neoprospecta General Information

Description

Developer of a biotechnology platform designed to help researchers deal with microbiological analysis, management, and control. The company's platform offers biocomputational analysis and quantitative PCR techniques which have created a line of rapid tests for the detection of microorganisms and antibiotic-resistance genes, enabling medical researchers to identify microorganisms using DNA sequencing technologies.

Contact Information

Ownership Status
Acquired/Merged
(Operating Subsidiary)
Financing Status
Formerly VC-backed
Corporate Office
  • Avenida Luiz Boiteux Piazza
  • Number 1302, Sapiens Parque, Canasvieiras
  • Florianopolis, 88054
  • Brazil
+55 (48)
Primary Industry
Biotechnology
Parent Company
Corporate Office
  • Avenida Luiz Boiteux Piazza
  • Number 1302, Sapiens Parque, Canasvieiras
  • Florianopolis, 88054
  • Brazil
+55 (48)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Neoprospecta Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Merger/Acquisition 29-Jan-2025 $8.28M Completed Generating Revenue
6. Later Stage VC 14-May-2021 Completed Generating Revenue
5. Secondary Transaction - Private 01-Feb-2024 Completed Generating Revenue
4. Later Stage VC 01-Jun-2016 Completed Generating Revenue
3. Early Stage VC 08-Aug-2014 Completed Generating Revenue
2. Early Stage VC 15-Feb-2013 $249K $249K Completed Generating Revenue
1. Accelerator/Incubator Completed Generating Revenue
To view Neoprospecta’s complete valuation and funding history, request access »

Neoprospecta Patents

Neoprospecta Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20160273031-A1 Method, kit and premix for quantitative and discriminative determination of nucleic acids, qdpcr; in vitro method for the quantitative and discriminative diagnosis of biological entities Inactive 18-Nov-2013
WO-2015070309-A1 Method, kit and premix for quantitative and discriminative determination of nucleic acids, qdpcr; in vitro method for the quantitative and discriminative diagnosis of biological entities Inactive 18-Nov-2013

Neoprospecta Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Neoprospecta Former Investors (7)

Investor Name Investor Type Holding Investor Since Participating Rounds
Associação Catarinense de Tecnologia Accelerator/Incubator
CRP Companhia de Participacoes Venture Capital Minority
CVentures Corporate Venture Capital Minority
Angel (individual) Minority
IDEE (Other Commercial Products) Venture Capital Minority
You’re viewing 5 of 7 investors. Get the full list »

Neoprospecta FAQs

  • When was Neoprospecta founded?

    Neoprospecta was founded in 2011.

  • Where is Neoprospecta headquartered?

    Neoprospecta is headquartered in Florianopolis, Brazil.

  • What is the size of Neoprospecta?

    Neoprospecta has 50 total employees.

  • What industry is Neoprospecta in?

    Neoprospecta’s primary industry is Biotechnology.

  • Is Neoprospecta a private or public company?

    Neoprospecta is a Private company.

  • What is the current valuation of Neoprospecta?

    The current valuation of Neoprospecta is .

  • What is Neoprospecta’s current revenue?

    The current revenue for Neoprospecta is .

  • How much funding has Neoprospecta raised over time?

    Neoprospecta has raised $2.49M.

  • Who are Neoprospecta’s investors?

    Associação Catarinense de Tecnologia, CRP Companhia de Participacoes, CVentures, , and IDEE (Other Commercial Products) are 5 of 7 investors who have invested in Neoprospecta.

  • When was Neoprospecta acquired?

    Neoprospecta was acquired on 29-Jan-2025.

  • Who acquired Neoprospecta?

    Neoprospecta was acquired by BioMérieux.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process